Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers

BACKGROUND: Comparisons of second‐line anti‐tumour necrosis factor (TNF) agents and vedolizumab are sparse. AIM: To evaluate the effectiveness of anti‐TNF agents compared to vedolizumab as second‐line biologics in inflammatory bowel disease (IBD). METHODS: A propensity score‐matched cohort was creat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rundquist, Sara, Sachs, Michael C., Eriksson, Carl, Olén, Ola, Montgomery, Scott, Halfvarson, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Anti‐tnfs Compared with Vedolizumab as Second‐line Biologics in IBD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898922/
https://www.ncbi.nlm.nih.gov/pubmed/33340426
http://dx.doi.org/10.1111/apt.16193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898922/
https://www.ncbi.nlm.nih.gov/pubmed/33340426
http://dx.doi.org/10.1111/apt.16193

Ejemplares similares